A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
Completed · Phase 2
Conditions studied: Chronic Kidney Failure, Vascular Graft Occlusion
In brief
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.
Key facts
- Study ID
- NCT00074620
- Run by
- Speedel Pharma Ltd.
- People needed
- 260
- Starts
- 2003-11-01
- Expected to finish
- 2006-01-01
- Last updated by the study team
- 2007-10-05
Who can join
Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pennsylvania Hospital - Franklin Dialysis Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.